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Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on ﬁrst-line
cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis.
Irinotecan has shown antitumour activity in human testicular tumour xenografts in nude mice. We have performed a phase II
study examining the single agent activity of irinotecan in patients with metastatic relapsed or cisplatin-refractory germ cell
cancer. Refractory disease was deﬁned as progression or relapse within 4 weeks after cisplatin-based chemotherapy or relapse
after salvage high-dose chemotherapy with autologous stem cell support. Irinotecan was administered at a dose of 300
(7350) mg m
72 every 3 weeks. Response was evaluated every 4 weeks. Fifteen patients have been enrolled. Median age was
35 (19–53) years. Primary tumour localisation was gonadal/mediastinal in 12/3 patients. Patients had been pretreated with a
median of six (4–12) cisplatin-containing cycles and 13 out of 15 patients had previously failed high-dose chemotherapy with
blood stem cell support. Median number of irinotecan applications was two (1–3). Fourteen patients are assessable for
response and all for toxicity. In one patient, no adequate response evaluation was performed. Toxicity was generally
acceptable and consisted mainly of haematological side effects with common toxicity criteria 38 anaemia (two patients),
common toxicity criteria 38 leukocytopenia (one patient) and common toxicity criteria 38 thrombocytopenia (three patients).
Common toxicity criteria 3/48 non-haematological toxicity occurred in ﬁve patients (33%): 16diarrhoea, 26alopecia,
16fever and in one patient worsening of pre-existing peripheral polyneuropathy from 18 to 48. No response was observed
to irinotecan therapy. Currently, 13 patients have died of the disease and two patients are alive with the disease. The patients
included in our study exhibit similar prognostic characteristics as patients treated in previous trials evaluating new drugs in this
setting. Irinotecan at a dose of 300–350 mg m
72 every 3 weeks appears to have no antitumour activity in patients with
cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justiﬁed.
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Today, approximately 70–80% of patients with metastatic germ
cell cancer can be cured with cisplatin-based combination
chemotherapy (Einhorn, 1990; Bosl and Motzer, 1997). Patients
who relapse after ﬁrst-line chemotherapy will achieve long-term
survival rates of only 20–50% following platinum-containing stan-
dard- or high-dose salvage chemotherapy. Patients progressing
during or relapsing after salvage chemotherapy exhibit an extre-
mely poor prognosis and long-term survival is achieved in less
than 5% of patients (Nichols et al, 1994; Porcu et al, 2000). The
identiﬁcation of new drugs with signiﬁcant antitumour activity
remains a priority in these heavily pretreated patients. Several
cytotoxic agents, including topotecan, vinorelbine, iproplatin,
paclitaxel, and more recently, bendamustine, gemcitabine and
oxaliplatin have been investigated in refractory germ cell cancer
patients (Drasga et al, 1987; Murphy et al, 1992; Bokemeyer et
al, 1993, 1996, 1999; Motzer et al, 1994; Puc et al, 1995; Einhorn
et al, 1999; Kollmannsberger et al, 2000, 2001). However, only
continuously applied low dose oral etoposide, paclitaxel, gemcita-
bine, and, most recently, oxaliplatin have thus far been able to
demonstrate response rates of about 13–20% in patients with
cisplatin-refractory germ cell cancer (Miller and Einhorn, 1990;
Motzer et al, 1994; Bokemeyer et al, 1996, 1999; Einhorn et al,
1999; Kollmannsberger et al, 2001).
Irinotecan (CPT-11; 7-ethyl-10 hydroxycamptothecin 10(1,4'-
biperidene)-carboxylat) is a topoisomerase-I inhibitor that blocks









Received 21 February 2002; revised 15 April 2002; accepted 14 July 2002
*Correspondence: C Bokemeyer, Department of Haematology/Oncology,
University of Tuebingen Medical Center, Otfried-Mueller-Str. 10, 72076
Tuebingen, Germany; E-mail: carsten.bokemeyer@med.uni-tuebingen.de
British Journal of Cancer (2002) 87, 729–732
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comsingle-strand DNA breaks eventually blocking cell division (Cree-
mers et al, 1994). No cross-resistance has thus far been reported
to other agents active in germ cell cancer such as cisplatin, ifosfa-
mide or bleomycin. Irinotecan has been approved for the ﬁrst- and
second-line treatment of metastatic colon cancer (Cunningham et
al, 1998; Douillard et al, 2000). Common side effects of irinotecan
include delayed diarrhoea, neutropenia, early cholinergic
syndrome, and nausea/vomiting. The dose-limiting toxicities are
severe diarrhoea and neutropenia. In vitro data demonstrated a
dose-dependent activity of irinotecan against human testicular
tumour xenografts (Miki et al, 1997). This provided the rationale
for the present study which evaluates irinotecan in pretreated
patients with refractory germ cell cancer.
PATIENTS AND METHODS
Eligibility requirements included the diagnosis of germ cell cancer
with evidence of tumour progression or relapse after at least two
previous adequate cisplatin-based chemotherapies or after salvage
high-dose chemotherapy with autologous stem cell support.
Patients with disease progression during their initial induction
chemotherapy or during salvage therapy were also eligible. Addi-
tional inclusion criteria were the presence of bidimensionally
measurable disease and/or elevated tumour markers, a Karnofsky
performance status 560% as well as adequate haematological
(WBC 42500 ml
71, platelets 475000 ml
71), renal (creatinine
clearance 460 ml min
71) and liver function (bilirubin 41.5-fold
upper normal value; liver enzymes 5three-fold upper normal
value). No other concomitant chemotherapy, radiotherapy or
experimental medication was allowed. All patients had to give their
written informed consent. The study was approved by the Univer-
sity of Tuebingen Ethics Committee.
Irinotecan was administered at a dose of 300 mg m
72 infused
over 30 min on day one, repeated every 3 weeks. In case of CTC
(common toxicity criteria) toxicity 481, a dose escalation to
350 mg m
72 was planned. Concomitant antiemetic therapy
included 5-HT3-antagonists as well as dexamethasone. A dose
reduction of 50% was planned in case of CTC 84 thrombocyto-
penia, granulocytopenia or neutropenic fever. No routine use of
G-CSF was recommended, but G-CSF could be given on an indi-
vidual basis in instances of severe neutropenia. A 25% and 50%
dose reduction was planned in case of CTC 83o r84 non-haema-
tological toxicity, respectively. All patients were treated on an
outpatient basis.
Deﬁnitions
Disease was considered cisplatin-refractory, when at least tumour
stabilisation or a remission was achieved, but tumour progression
occurred again within 4 weeks of the last cisplatin-based
chemotherapy. Disease was considered absolutely cisplatin-refrac-
tory, when tumour progression developed while receiving
cisplatin-based therapy (Nichols et al, 1989; Beyer et al, 1996).
Response and toxicity were graded according to WHO and NCI-
CTC (version 2.0) criteria, respectively (Miller et al, 1981). In addi-
tion, reduction of the size of a tumour lesion and normalisation of
previously elevated tumour markers was considered a partial remis-
sion with tumour marker normalisation (PR7), whereas a
reduction 50% in the sum of the perpendicular diameters of
measurable disease plus a tumour marker decrease of 450% for
at least 1 month, but without complete normalisation, was consid-
ered a marker positive partial remission (PR+). Serum tumour
markers were determined every 3 weeks. Evaluation of measurable
disease by radiographic means was performed every 4 weeks. All
responses as well as the diagnosis of stable disease had to be re-
conﬁrmed after a 4-week interval. All patients were scheduled to
receive at least two cycles of treatment. However, in case of a
signiﬁcant marker (50%) and/or radiological progression (25%)
after one cycle, the treatment was stopped and the patient was clas-
siﬁed as having progressive disease. In patients with tumour
responses or disease stabilisation therapy was planned to be contin-
ued for at least two more cycles after achievement of the best
response unless severe toxicity occurred.
Statistical considerations
The sequential two-step statistical design of Gehan was used to
determine the number of patients required (Gehan, 1961). A
response rate of clinical interest of 20%, which is comparable to
other active drugs in this therapeutic situation, was assumed. Based
on a signiﬁcance level of 0.05 and a power of 80%, initially 14
patients had to be included. If no responses were observed, the trial
would be closed because if the true response rate was at least 20%,
then the probability of obtaining no responses in 14 patients was
less than 5%. In case of one response, the number of patients
required for the second step was to be calculated based on the total
number of responders within the ﬁrst 14 patients.
Survival and follow-up time were calculated from the beginning
of irinotecan therapy until the date of death or the date of last
follow-up using the Kaplan–Meier test.
RESULTS
Fifteen patients were entered into the study between November
2000 and September 2001. Patient characteristics are listed in Table
1. A total of 28 cycles of irinotecan were applied with a median of
two cycles (range 1–3 cycles) per patient. Most patients presented
with lung (87%) and lymph node (67%) metastases. Eight (53%)
patients had liver involvement and three (20%) had brain metas-
tases. Two (13%) patients had relapsed later than 2 years
following initial therapy and 11 (73%) patients were considered
to have platinum refractory or absolutely platinum refractory
disease (Nichols et al, 1989; Beyer et al, 1996). All patients were
heavily pretreated with a median number of six (range: 4–12)
cisplatin-containing chemotherapy cycles prior to irinotecan ther-
apy. Thirteen patients (87%) had previously received carboplatin/
etoposide-based high-dose chemotherapy with autologous stem cell
support. In addition 12 (80%) patients were pretreated with pacli-
taxel, six (40%) with oxaliplatin and two (13%) with gemcitabine.
No objective response was observed within our cohort of 15
relapsed or cisplatin refractory patients. All patients progressed
during the ﬁrst or second cycle of therapy. Irinotecan was well
tolerated in this patient population (Table 2). Five patients
(30%) developed CTC 83/4 non-haematological side effects, one
patient diarrhoea, two patients worsening of alopecia from 81t o
83 and 84, one patient a non-neutropenic infection and in one
patient pre-existing polyneuropathy worsened from 81t o84.
Haematological toxicity was acceptable despite previous use of
high-dose chemotherapy plus autologous stem cell support in
almost all patients. Only three patients (20%) developed a CTC
83 thrombocytopenia and two patients (13%) CTC 83 anaemia.
Forty-seven per cent of patients developed a CTC 18/28 and one
patient a 83 leucocytopenia. There were no cases of granulocyto-
penic fever or therapy-related mortality. After a median follow-
up of 3 months (range 1–9 months) 13 patients (87%) have died
and two patients (13%) are alive with disease. Median overall
survival for all patients was 3 months (range 1–9).
DISCUSSION
In recent years several new drugs have been systematically investi-
gated for the treatment of patients with cisplatin-refractory
testicular cancer. This exploration of new drugs has mostly
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setting, however, may not only allow palliative therapy for refrac-
tory patients but may also offer new possibilities for the
development of combination therapy. Only very few of the cyto-
static agents studied so far, in particular etoposide, ifosfamide or
more recently paclitaxel have been found active in patients with
refractory germ cell cancer and were subsequently incorporated
into combination regimens. Due to its activity in refractory
patients, paclitaxel was investigated as part of combination
chemotherapy regimens in the salvage setting and is now studied
in combination with the standard-PEB regimen as ﬁrst-line treat-
ment (Motzer et al, 2000) Two further agents, gemcitabine and
oxaliplatin, have been reported to yield response rates of 13–
19% in this patient population (Bokemeyer et al, 1999; Einhorn
et al, 1999; Kollmannsberger et al, 2001).
The present phase II study investigates the activity of irinotecan
in patients with intensively pretreated or cisplatin-refractory germ
cell cancer. The rationale for the evaluation of irinotecan in testis
cancer was based on the dose-dependent antitumour effect of
irinotecan observed in human testicular tumour xenografts in nude
mice either applied as single agent or in combination with cisplatin
(Miki et al, 1997). A subsequent phase II study by Nomoto et al
(2000) reported a very high response rate of 57% for the combina-
tion of irinotecan and cisplatin or nedaplatin in 14 cisplatin-
refractory germ cell cancer patients suggesting that irinotecan
may also be clinically active in refractory patients. No full report
of the study by Nomoto et al (2000) has been published thus far
and no data are available about the previous chemotherapy treat-
ment, the response rate to previous treatment or the deﬁnition
of ‘cisplatin-refractory disease’, which makes the correct interpreta-
tion of these results impossible. However, in our phase II study, no
objective remission was observed in a cohort of 15 patients indicat-
ing that single agent irinotecan has no clinical antitumour activity
in relapsed or cisplatin-refractory patients. Based on the negative
results of our study, we assume that primarily cisplatin contributed
to the response rate achieved in the Japanese study (Nomoto et al,
2000).
The patients in our study exhibited very unfavourable prognostic
characteristics which may have prevented the activity of irinotecan.
However, the patient population studied here was comparable to
those who had been included in previous studies by our group inves-
tigating paclitaxel, gemcitabine or oxaliplatin in the refractory setting
(Bokemeyer et al, 1996, 1999; Kollmannsberger et al, 2001). Consid-
ering the supposed preclinically dose-dependent efﬁcacy of
irinotecan, a very low dose of irinotecan might lead to negative clin-
ical results. In our study, we administered irinotecan at a dose of
300 mg m
72every 3weeks with the plan to intraindividually increase
the dose to 350 mg m
72 in case of good tolerability (4CTC 81 toxi-
city). This dose is very close to the ofﬁcially approved single agent
dose of irinotecan of 350 mg m
72, which has also been the maxi-
mally tolerated dose proposed from phase I studies. The starting
dose of 300 mg/m
72 was chosen in order to prevent severe myelo-
suppression since nearly all patients were heavily pretreated
including high-dose chemotherapy with autologous stem cell
support. In addition, most patients developed at least 81o r82 haema-
tological toxicity indicating that the irinotecan dose was adequate for
this patient population in our study and under-dosing may not be a
likely explanation for the lack of activity of irinotecan in our study.
Irinotecan is the second topoisomerase I inhibitor which was
evaluated in cisplatin-refractory germ cell cancer based on favour-
able preclinical data. Topotecan has also been shown to possess no
clinical activity in this therapeutic setting (Puc et al, 1995). Thus,
in contrast to topoisomerase II inhibitors, particularly etoposide,
topoisomerase I inhibitors appear to be ineffective and this thera-
peutic principle seems to play no role in the treatment of germ cell
cancer.
The good tolerability of irinotecan in this heavily pretreated
group of patients was, however, remarkable. Haematological toxi-
city was acceptable, even in patients who had previously received
high-dose chemotherapy plus autologous stem cell support. The
treatment of patients, who may have a limited bone marrow func-
tion and thus are likely to develop an increased haematological
toxicity, still remains a therapeutic challenge. Only few agents have
been systematically investigated in this respect and were found to
be feasible in this setting, among them paclitaxel, gemcitabine
and bendamustine (Bokemeyer et al, 1996; Bregni et al, 1998;
Constenla et al, 1998; Sola et al, 1999; Kollmannsberger et al,
2000). In all of them, thrombocytopenia appears to be more
frequent than granulocytopenia. Thus, irinotecan’s acceptable toxi-
city proﬁle makes it a potential therapeutic option for the palliative
treatment of heavily pretreated patients with cancer types for which
a higher level of antitumour activity can be expected (Rosen, 1998;
Rocha-Lima et al, 2001; Takeda et al, 2001; Ueoka et al, 2001). The










Table 1 Patient characteristics (n=15)
Number of patients included and assessable 15
Median age (years) 35 [19–53]






Lymph nodes 10 (67%)
Median number of platinum-containing cycles during
previous therapy 6 [4–12]
Number of patients pretreated with high-dose chemotherapy
plus autologous stem cell support 13 (87%)
Number of patients with prior paclitaxel-Ctx 12 (80%)
Number of patients with prior gemcitabine-Ctx 2 (13%)
Late relapse 42 years 2 (13%)
Number of patients with platinum refractory disease* 7 (47%)
Number of patients absolutely platinum refractory disease** 4 (27%)
*, **See section Patients and methods (Deﬁnitions).





No. (%) No. (%)
Haematological:
Leucocytopenia 7 (47) 1 (7)
Thrombocytopenia 5 (33) 3 (20)
Anaemia 12 (80) 2 (13)
Non-haematological:
Nausea/Vomiting 7 (47) 0
Fever 2 (13) 1 (7)
Diarrhoea 0 1 (7)
Liver enzyme elevation 1 (7) 0
Neurotoxicity 0 1 (7)
Other 5 (30) 0
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